Illumina, Inc. Common Stock Ex-distribution When-Issued
ILMNV
NASDAQ107.00
USD
+1.75
- -
Return %
Stock
S&P500
1Y
1,069,999,900.00
23.08
3Y
1,069,999,900.00
67.59
5Y
1,069,999,900.00
74.74
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jacob Thaysen
- Full Time Employees
- 10,590
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- United States of America
- Similar Companies
- Business
- Illumina, Inc. develops, manufactures and markets integrated systems for genetic variation analysis and biological function, including DNA sequencing instruments, consumables and array-based technologies for genomics research, clinical diagnostics, oncology, reproductive health, infectious diseases and proteomics applications. The company offers next-generation sequencing platforms such as NovaSeq X series, reagents including sequencing kits, flow cells and library preparation materials; microarray products for genotyping, gene expression and protein analysis; and services encompassing whole-genome sequencing, non-invasive prenatal testing, instrument maintenance, training and consulting. Founded in 1998 and headquartered in San Diego, California, Illumina operates manufacturing facilities in the US, Singapore, the UK, the Netherlands, China and India, serving customers in genomic research centers, academic institutions, government labs, hospitals, pharmaceutical and biotechnology firms across more than 165 countries in the Americas, Europe, Middle East, Africa and Asia-Pacific. In June 2025, Illumina entered a definitive agreement to acquire SomaLogic from Standard BioTools for $350 million in cash plus up to $75 million in milestones and royalties, integrating SomaLogic's aptamer-based proteomics platform to advance its multiomics strategy, enhance NovaSeq X capabilities and expand into high-throughput proteomics with expected profitability by 2027. In September 2025, the company launched BioInsight, a new business unit developing data assets, software and AI solutions to accelerate drug target discovery, biological pathway analysis and multiomic insights for pharmaceutical partners. These initiatives build on prior efforts including the 2024 GRAIL spin-off, positioning Illumina for growth in precision health and emerging life sciences segments.